Arterial hypertension in diabetes mellitus: From theory to clinical practice

Hippokratia

Volumn 12, Issue 2, 2008, Pages 74-80

  Sampanis, C ^a,b   Zamboulis, C ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Arterial hypertension diabetes mellitus

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; IRBESARTAN; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ALCOHOL ABSTINENCE; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BRAIN INFARCTION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; REVIEW; RISK FACTOR; SODIUM RESTRICTION; STROKE; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 41549126670     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Ebstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-418
2. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in The Multiple Risk Intervention Trial. Diabetes Care 1993; 16:434-444
3. Cooper ME. Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998; 352:213-219
4. Renal Data System. USRDS 1998 annual data report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Disease, April 1998 (NIH publication no. 98-3176)
5. National Diabetes Information Clearinghouse. Diabetes Statistics. Bethesda, MD: National Institutes of Health, 2000. NIH publication 02-3892
6. Bakris G. Pathogenesis of hypertension in diabetes. Diabetes Reviews 1995; 3: 460-474
7. Parving HH, Andersen AR, Smidt UM. Diabetic nephropathy and arterial hypertension. Diabetologia 1983; 24:10-12
8. Vora J, Dolben J, Dean JD, et al. Renal hemodymanics in newly presenting non-insulin-dependent diabetes. Kidney Int 1992; 41:829-835
9. Mykkanen L, Haffner SM, Kuusisto J, et al. Microalbuminuria precedes the development of NIDDM. Diabetes 1994; 43: 552-557
10. Lafferty AR, Werther GA, Clarke CF. Ambulatory blood pressure, microalbuminuria, and autonomic nephropathy in adolescents with type 1 diabetes. Diabetes Care 2000; 23: 533-538
11. Pecis M, Azevedo MJ, Moraes RS, et al. Autonomic dysfunction and urinary albumin excretion rate are associated with an abnormal blood pressure pattern in normotensive normoalbuminuric type 1 diabetic patients. Diabetes Care 2000; 23: 989-993
12. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347:797-805
13. Earle K, Viberti GC. Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease. Kidney Int 1994; 45: 434-437
14. Mangili R, Bending JJ, Scott G, et al. Increased sodium-lithium countertransport activity in red cells of patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1988; 318:146-150
15. Rosskopf D, Fromter E, Siffert W. Hypertensive sodium-proton exchanger phenotype persists in immortalized lymphoblasts from essential hypertensive patients: a cell culture model for human hypertension. J Clin Invest 1993; 92: 2553-2559
16. Lurbe A, Fioretto P, Mauer M, et al. Growth phenotype of cultured skin fibroblasts from IDDM patients with and without nephropathy and overactivity of the Na+/H+ antiporter. Kidney Int 1996; 50: 1684-1693
17. Sowers JR, Epstein M, Frolich ED. Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001; 37: 1053-1059
18. McFarlane SL, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-718
19. Williams B. Insulin resistance: the shape of things to come. Lancet 1994; 344:521-524
20. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689
21. Stern S, Grosskopf I, Shapira I, et al. Risk factor clustering in hypertensive patients: impact of the reports of NCEP-II and second joint task force on coronary preventionon JNC-6 guidelines. J Intern Med 2000; 248: 203-210
22. De Fronzo RA, Bonnadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992; 15: 318-368
23. El-Atat F, Aneja A, Mcfarlane S, Sowers JR. Obesity and Hypertension. Endocrinol Metab Clin North Am 2003; 32: 823-854
24. Grunfeld B, Balzareti M, Romo M, et al. Hyperinsulinemia in normotensive offspring of hypertensive patients. Hypertension1994; 23 (Suppl 1): 112-115
25. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286: H1597-H1602
26. El-Atat FA, Sameer NS, Mcfarlane SI, Sowers JR. Relationship between Hyperinsulinemia, Hypertension and Progressive Renal Disease. J Am Soc Nephrol 2004; 15:2816-2827
27. Vettor R, Mazzonetto P, Macor P, et al. Effect of endogenous organic hyperinsulinemia on blood pressure and serum triglycerides. Eur J Clin Invest 1994; 24: 350-354
28. Castro JP, El-Atat FA, McFarlane SI, et al. Cardiometabolic syndrome: Pathophysiology and treatment. Curr Hypertens Rep 2003; 5: 393-401
29. Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk of hypertension in women. Ann Intern Med 1998;128: 81-88
30. Pell S, D'Allonzo CA. Some aspects of hypertension in diabetes mellitus. JAMA 1967; 202: 104-110
31. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989; 12: 464-447
32. Hasslacher C, Ritz E, Wahl P. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989; 4: 859-863
33. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363-2369
34. U.S. Renal Data System. USRDS 2001 Annual Data Report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Disease, 2001
35. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661
36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
37. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensine-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 34: 370-379
38. Mathiesen R, Hommel E, Hansen HP, et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999; 319: 24-25
39. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-analysis. Ann Intern Med 1993; 118: 129-138
40. Gerstein HC, Yusuf S, Mann JFE, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICR?-HOPE substudy. Lancet 2000; 355: 253-259
41. Parving HH, Lehnert H, Mortensen JB, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-876
42. Lewis EJ, Hunsicker LG, Clarke WR. The Collaborative Study Group: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
43. Brenner BM, Cooper ME, Zeeuw D, et al. The RENAAL Study Investigators: Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
44. Mogensen CE, Neldam S, Tikkanen L, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes : the Candesartan and Lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440-1444
45. Andersen NH, Poulsen PL, Knudsen ST, et al. Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes (The CALM II study). Diabetes Care 2005; 28: 273-277
46. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63: 1874-1880
47. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26: 2268-2274
48. Barnett AH, Bain SC, Bouter P, et al. The Diabetics Exposed to Telmisartan and Enalapril Study Group. N Engl J Med 2004; 351: 1952-1961
49. Ruggeneti P, Fassi A, Parvanova Ilieva A, et al. The Bergamo Nephrologic Complications Trial (BENEDICT) Investigators: Preventing Microalbuminuria in Type 2 Diabetes. N Engl J Med 2004; 351: 1941-1951
50. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
51. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
52. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy: British trial shows clear effects of treatment, especially blood pressure reduction. BMJ 1998; 317 :693-694
53. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762
54. Ruilope LM, Garcia-Robles R. How far should blood pressure be reduced in diabetic patients? J Hypertens Suppl 1997; 15: S63-S65
55. Franklin SS, Gustin W, Wong ND, et al.. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 1997; 96: 308-315
56. Staessen JA, Fagard R, Thijs L, et al. Sub-group and per-protocol analysis of the randomized European Trial of Isolated Systolic Hypertension in the Elderly. Arch Intern Med 1998; 158: 1681-1691
57. Lindholm LH, Hansson H, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1871-1875
58. Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000; 160: 2447-2452
59. Burt V, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-313
60. Kohner EM. Effect of diuretic therapy on glucose tolerance in hypertensive patients. Lancet 1971; 1: 986-990
61. Gurwitz HJ, Bohn RL, Glynn RJ, et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med1993; 118: 273-278
62. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension Study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003
63. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the stroke council of the American Heart Association. Circulation 2001; 103: 163-182
64. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention. JAMA 2002; 288: 1388-1395
65. Eguchi K, Kario K, Shimada K. Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke 2003; 34: 2471-2474
66. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
67. Bakris GL, Gaxiola E, Messerli FH, et al. Clinical outcomes in the diabetes cohort of the International Verapamil SR Trandolapril study. Hypertension 2004; 44: 637-642
68. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-2231
69. McFarlane SI, Sica DA, Sowers JR. Stroke in Patients With Diabetes and Hypertension. J Clin Hypertens 2005; 7: 286-292
70. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003; 289: 2560-2572
71. Position Statement. Hypertension management in adults with diabetes. Diabetes Care 2004; 27: S65-S67
72. Compendium of ESC Guidelines 2007, Section III: Diabetic Heart Disease, Eds. Lippincott Williams and Wilkins, 2007; 33-52
73. Zanella MT, Kohlmann O, Ribeiro AB. Treatment of Obesity Hypertension and Diabetes Syndrome. Hypertension 2001; 38 [part 2]: 705-708
74. Weir MR. Diabetes and Hypertension: How Low Should You Go and With Which Drugs? Am J Hypertens 2001; 14: S17-S26
75. Bakris GL. The Importance of Blood Pressure Control in the Patients with Diabetes. Am J Med 2004; 116(5A): S30-S38
76. Kaplan NM. Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence. Ann Intern Med 2001; 135: 1079-1083
77. Christensen PK, Hansen HP, Parving HH. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997; 52: 1369-1374
78. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955-1964
79. Knight EL, Bohn RL, Wang PS, et al. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 2001; 38: 809-814
80. Douglas JG, Ferdinand KC, Bakris GL, Sowers JR. Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained. Postgrad Med 2002; 112: 51-62
81. Hart PD, Bakris GL. Hypertension Control Rates: Time for Translation of Guidelines into Clinical Practice. Am J Med 2004; 117: 62-64
82. Gaede P, Vedel P, Larsen N, et al. Multifactorial Intervention and Cardiovascular disease in Patients with Type 2 Diabetes. N Engl J Med 2003; 348: 383-393